Secretome Therapeutics Started STM-01 Clinical Trial
The company has launched a Phase 2 study for Duchenne muscular dystrophy patients in the United States.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe developing novel cell therapies for rare diseases should be a national health priority?
Secretome Therapeutics initiated the THRIVE-2 Phase 2 clinical study to evaluate the safety and efficacy of its investigational therapy, STM-01. The trial focuses on treating patients suffering from Duchenne muscular dystrophy.
Why it matters
The therapy seeks to combat the progressive skeletal and cardiac muscle degeneration characteristic of Duchenne muscular dystrophy. By using neonatal cardiac progenitor cells, the treatment aims to address chronic inflammation and fibrosis.
STM-01 is a biologic therapy derived from neonatal cardiac progenitor cells designed to modulate pathways involved in tissue repair. The trial evaluates efficacy by assessing both skeletal muscle and cardiac function in patients.
The players
Secretome Therapeutics
This Plano, Texas-based biotechnology company focuses on developing advanced regenerative therapies for complex medical conditions.
The details
The study, which is now open for enrollment at various sites across the United States, utilizes the anti-inflammatory and anti-fibrotic properties of STM-01 to intervene in biological degeneration. It represents a significant effort to stabilize muscle tissue in patients diagnosed with this condition.
Timeline
Secretome Therapeutics announced the initiation of the study on September 29, 2026.
The Tech Race
This development highlights the ongoing shift toward regenerative medicine in the treatment of rare genetic diseases. It follows a pattern of replacing traditional symptom-management drugs with therapies designed to actively repair tissue at the cellular level.
For families affected by Duchenne muscular dystrophy, the opening of this study offers a potential new pathway for treatment within the United States. Prospective participants should consult with their physicians to determine if they meet the criteria for this open-label trial.
The takeaway
This study underscores the increasing use of neonatal cardiac progenitor cells in addressing muscle-wasting diseases. Patients and caregivers should stay informed on enrollment criteria to evaluate if such experimental therapies might align with their long-term care plans.
What happens next
The company expects to enroll the first patient for the THRIVE-2 study imminently.
Further reading
For more information on the latest advancements in the field, visit the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe developing novel cell therapies for rare diseases should be a national health priority?
